MSCV-IRES-GFP ASXL1 (p.G646 Wfs *12) 3x FLAG Citations (1)

Originally described in: Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, Lahdesmaki H, Rao A Nat Commun. 2015 Jun 22;6:7307. doi: 10.1038/ncomms8307. PubMed Journal

---

Articles Citing MSCV-IRES-GFP ASXL1 (p.G646 Wfs *12) 3x FLAG

Articles

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. Maslah N, Kaci N, Roux B, Alexe G, Marie R, Pasquer H, Verger E, De Oliveira RD, Culeux C, Mlayah B, Gauthier N, Gonzales F, Zhao LP, Ganesan S, Gou P, Ling F, Soret-Dulphy J, Parquet N, Vainchenker W, Raffoux E, Padua RA, Giraudier S, Marty C, Plo I, Lobry C, Stegmaier K, Puissant A, Kiladjian JJ, Cassinat B, Benajiba L. Nat Commun. 2025 Jul 8;16(1):6270. doi: 10.1038/s41467-025-60884-1. PubMed

If you have published an article using this material, please email us at to have your article added to this page.